A diverse array of genetic factors contribute to the pathogenesis of Systemic Lupus Erythematosus
© Tiffin et al.; licensee BioMed Central Ltd. 2013
Received: 12 November 2012
Accepted: 1 January 2013
Published: 7 January 2013
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with variable clinical presentation frequently affecting the skin, joints, haemopoietic system, kidneys, lungs and central nervous system. It can be life threatening when major organs are involved. The full pathological and genetic mechanisms of this complex disease are yet to be elucidated; although roles have been described for environmental triggers such as sunlight, drugs and chemicals, and infectious agents. Cellular processes such as inefficient clearing of apoptotic DNA fragments and generation of autoantibodies have been implicated in disease progression. A diverse array of disease-associated genes and microRNA regulatory molecules that are dysregulated through polymorphism and copy number variation have also been identified; and an effect of ethnicity on susceptibility has been described.
KeywordsSystemic lupus erythematosus Autoimmunity Genetic susceptibility Apoptosis dsDNA Disease genes
The development of SLE can be categorized into several phases with a cumulative effect. Initially, an interplay between environment, hormonal and genetic factors results in decreased immunologic tolerance towards certain self antigen. This systemic autoimmunity then results in increased serum antinuclear and anti-glomerular autoantibodies, leading to an enhanced autoimmune repertoire; and aberrations in both the innate and adaptive arms of the immune system play an important role in the genesis and progression of lupus. Finally, immunological events occur within the target organ and result in end organ damage [4, 5].
Studies of racial tendencies show that SLE occurs more frequently in non-Caucasian individuals, supporting a role for genetic predisposition to SLE. In America, SLE is more frequent in African-Americans, Hispanics and Asians than in Caucasians, and has been described to be three to four times higher among African-American women compared to Caucasian women . The past half century has seen a ten-fold increase in the annual incidence of SLE in industrialized Western countries [7, 8], with estimates of prevalence in the UK at 25 per 100 000, and incidence approximately 1 (males) - 8 (females) per 100 000 [9–11]. The epidemiology of SLE in the developing world remains largely unknown due to poor disease recognition, poor diagnostic tools and supposed “rarity” of SLE in tropical areas [12–14]; people of African and Asian extraction living in industrialized countries, however, demonstrate the highest prevalence rates in the world [7, 15]. Racial admixture  and increased exposure to environmental factors such as tobacco products and viral infections are thought to increase the risk in people of African or Asian extraction living in industrialized countries . Tropical infections such as malaria, on the other hand, appear to offer protection from SLE . Although some of these differences in population prevalence of SLE may be explained by the effects of environmental differences, genetic differences between populations clearly contribute to the complexities of SLE pathogenesis .
Cellular mechanisms underlying SLE
During apoptosis, several proteins and nuclear materials (DNA and RNA) are modified by cleavage, facilitating specific, apoptosis-induced post-translational modifications of autoantigens (e.g. methylation, phosphorylation, ubiquitination and citrullination). Normally apoptotic cells are quickly removed by phagocytosis before release of their modified contents. In SLE, however, removal of apoptotic cells is dysregulated and the blebs and their modified contents are exposed to the immune system at the cell surface, resulting in recognition as non-self antigens (danger signaling) . Dendritic cells (DCs) become activated by the modified autoantigens, leading to an immunogenic response and the formation of autoantibodies. Autoimmunity in SLE thus occurs when self-molecules evoke an immunologic challenge that activates the immune system and stimulates host defense mechanisms . This ‘danger’ signaling can induce autoimmunity in susceptible individuals through exogenous (pathogen-associated molecular patterns – PAMPs) or endogenous (damage-associated molecular patterns – DAMPs) pathways, in which DNA and RNA exhibit important immunological activity . The PAMPs can also activate effector and regulatory T-cells, break tolerance and stimulate self-reactive B-cells . Recent evidence has shown that toll-like receptors (TLRs) associated with these danger molecules mediate the signaling pathways that over-ride the peripheral tolerance mechanisms, and promote and sustain chronic inflammation and autoimmune diseases [27, 28]. Engagement of TLRs may serve two functions: (i) up-regulation of co-stimulatory molecules (CD80/CD86) which play an important role in the activation of chromatin-specific T helper cells , and (ii) up-regulation of certain matrix metalloproteases (MMP2 and MMP9) with the potential to cause significant damage in the kidney in SLE patients [30, 31]. Taken together, apoptosis and poor clearance of apoptotic materials are therefore key processes in the pathogenesis of SLE.
Genetic factors contributing to SLE
High heritability, monozygotic and dizygotic twin studies [32–34], and incidence in first and second-degree relatives [35, 36] and siblings  all indicate a substantial genetic component to SLE. Many linkage and association studies also indicate regions of the genome associated with the disease. Finally, a clear demonstration of susceptibility differences by different ethnic groups suggest that genetic diversity underlies such differences, and that certain genetic backgrounds may alter the likelihood of developing SLE (reviewed in ).
Aetiological genes for SLE were initially identified by a hypothesis-driven approach, where candidate genes were assayed for variants prevalent in patients compared to healthy controls. The candidate gene approach best identifies single genes of high aetiological effect, in a Mendelian model of disease where mutation of one gene causes a disease phenotype. Disease gene identification has since shifted to a complex model of disease genetics, in which multiple genes have small effects that together contribute to the disease phenotype . New technologies enable genome-wide association studies, where disease association with all SNPs across the genome can be tested in one experiment, [40–42] requiring no pre-existing hypotheses about the disease mechanisms, and generating new hypotheses about disease mechanisms. Furthermore, next generation sequencing techniques make more attainable the sequencing of entire genomes of patients and case controls in order to identify aetiological variants . Candidate gene studies have identified multiple aetiological variants in MHC class II receptor, Fcγ receptor gene and complement cascade (C1a, C2 or C4) gene families.
Linkage analyses of affected families have identified SLE-susceptibility loci containing strong candidate genes, but in general have not provided necessary resolution to identify individual disease variants. Genome-wide association studies (GWAS), however, have rapidly increased the identification of SLE genes. The majority of GWAS for SLE to date are on European and Asian population patient/control populations (reviewed in , ), with limited studies being conducted in African American populations despite a higher incidence of SLE in this group . Genes that have been identified to date as causative genes for SLE are summarised in Additional file 1: Table S1.
Functions of SLE-associated genes
The genes that have been identified to date as aetiological genes for SLE are predominantly implicated in immunity and immunoglobulin binding, and inflammatory response. Analysis of Gene Ontology functional annotation of these genes, as described in , shows the top five most significantly overrepresented functions to be “protein binding”, “immune system process”, “immune response”, “immunoglobulin binding” and “protein complex binding”. The top thirty associated Gene Ontology annotations are shown in Additional file 2: Table S2 and Additional file 3: Diagram S3. These terms are consistent with a phenotype that entails activation of an autoimmune response, resulting in aggregation of immune complexes.
Although a substantial list of genes is associated with SLE through GWAS and candidate gene studies, it is still unclear how these genes may be contributing to the disease phenotype, and this is also confounded by the complex disease model where multiple genes are anticipated to each make small contributions to the disease state . Also, in many cases the genes are associated to SLE through the ‘tagging SNPs’ – so the identified SNP is not necessarily aetiological but rather a marker for the discrete region of the genome (haploblock) containing the disease variant .
SLE- associated single nucleotide polymorphisms
Altering a single base within the gene sequence can cause an altered, or disease phenotype. Changing the DNA sequence can result in a different amino acid appearing in the translated protein (a non-synonymous SNP); or a deletion or insertion of bases can cause a frameshift mutation in the DNA whereby the protein structure is significantly altered and often prematurely truncated. SNPs in the regulatory sequence around a gene may result in changes in the rate of synthesis or degradation of proteins, or alter mRNA splicing events that define final gene structure. To date, no single SNP has been associated with a functional change at the protein level in patients with SLE (although a recent study describes reduced Ets1 binding to the promoter of miR-146a due to a functional SNP, resulting in reduced expression, described in section 7.2.4 ). With increased understanding of genetics underlying disease, however, new elements of gene regulation are being investigated in the disease state, yielding some surprising results in SLE cohorts.
Gene copy number variation in SLE
Copy number variation (CNV) arises when a section of the genome containing an entire gene or genes is replicated or deleted, causing extra copies of the gene in one individual compared to another . The net effect of CNV is commonly an alteration in gene expression – altered gene ‘dosage’ - with a consequent downstream amplification or attenuation of the gene’s function. CNV has been shown for SLE-associated genes: low copy number of complement component 4 (C4a/C4b)  and Fcγ receptor 3B (FCGR3B) genes increases risk of SLE, whereas more copies of these genes have a protective effect. Complement component 4 is involved in the clearance of apoptotic debris and immune complexes , and an increase in complement expression could increase this function and thus protect against the aggregation of antibodies seen in SLE. Additionally, deficiency of C4 has been extensively reported in SLE patients (reviewed in ). The Fcγ receptors bind the Fc domain of IgG antibodies and regulate immune responses via tyrosine phosphorylation of their active cytoplasmic domains. FCGR3B is a functional regulator of neutrophil activation through altered IgG binding, and had been known to play a role in susceptibility to, and severity of SLE (reviewed in ).
Dysregulation of microRNA in SLE
MicroRNAs (miRNA) are regulatory molecules that are increasingly implicated in transcriptional dysregulation associated with disease [58, 59]. These are short (25 nucleotide) single-stranded non-coding RNA molecules that are processed from primary transcripts into stem-loop-stem structures and finally to functional single stranded RNA. This processed miRNA is complementary to a section of the target mRNA molecule, and will thus bind to and inhibit mRNA translation or initiate mRNA degradation (reviewed in ). miRNA molecules regulate transcriptional networks in this way, with central roles in some cancers, cell development, inflammatory response and neurodegenerative disorders [61–63]. The role of miRNA molecules in regulation of innate and adaptive immunity and autoimmunity has been reviewed extensively; and pertinent to the predominance of SLE (and other autoimmune diseases) in women, the regulation of immune system miRNAs by estrogen is also discussed [59, 64].
In 2007, Dai et al.  examined miRNA expression in peripheral blood mononuclear cells (PBMC) from 23 SLE patients compared to 10 healthy controls, indentifying seven consistently downregulated miRNAs in the disease state (miR-196a, miR-17-5p, miR-409-3p, miR-141, miR-383, miR-112 and miR-184), and nine upregulated miRNAs (miR-189, miR-61, miR-78, miR-21, miR-142-3p, miR-342, miR-299-3p, miR-198 and miR-298). In further studies on a subset of SLE patients, 36 upregulated and 30 downregulated miRNAs were identified in lupus nephritis (LN) patients compared to controls ; and 29 and 50 differentially expressed miRNAs were found in African American and European American LN patients respectively . Further studies identified MiR-148a and MiR-21 as key microRNA molecules in lupus, with a role for both in DNA hypomethylation in the disease state . MiR-21 is again implicated in SLE, with a proposed role in T-cell response through regulation of PDCD4 . MiRNA-126 contributes to SLE by targeting DNA methylation , and downregulation of miR-181-a has been associated with paediatric cases of SLE . An assay of miRNA-146a in PBMCs shows downregulation in SLE patients in two independent studies [72, 73], and underexpression of this microRNA may underlie SLE through dysregulation of the type 1 interferon pathway . Recently, a SNP in the promoter of miR-146a was shown to decrease binding of the transcriptional factor Ets1 with concomitant decreased expression of the microRNA molecule. This may in turn cause upregulation of the type I IFN pathway, as seen in these patients . Decreased levels of miR-146a (and miR-155) in serum from SLE patients has been shown in a further study , and the level of miR-155 is shown to be downregulated in regulatory T-cells from SLE patients .
The type of microRNA dysregulation associated with SLE can also be indirect, for example Divekar et al.  also show downregulation of gene expression for Dicer in regulatory T-cells from SLE patients. Dicer is the endoribonuclease that processes precursor microRNA molecules to generate functional microRNAs (described in ), suggesting that the milieu of active microRNA molecules may generally be altered in regulatory T-cells from SLE patients due to changes in miRNA processing. In another study, Hikami et al.  show that in a cohort of SLE patients, a disease-associated polymorphism in the 3’-untranslated region of the SPI1 gene falls in a binding region for miR-569.
There is ever-growing evidence that microRNA regulation is altered in the disease state; and specifically in SLE. Further research in this field will need to bring together the different strands of evidence for a more cohesive picture of microRNA regulation, and dysregulation in SLE. A summary of some of the miRNA molecules implicated in SLE is shown in Additional file 4: Table S4.
Mouse models for SLE
Several mouse strains spontaneously develop a disease that closely resembles SLE, resulting in the production of autoantibodies, followed by development of immune molecule complexes in the kidneys with associated damage; and include the strains MRL-Fas lpr , BXSB.Yaa, the F1 hybrid between NZB and NZW, and inbred derivatives of these strains . Over 100 regions in the mouse genome have been associated with SLE in the mouse by linkage analysis. These regions are called quantitative trait loci (QTL) and are extensively reviewed by Morel (2010) . Some mouse SLE QTL can also be shown to overlap with human QTL associated with lupus heritability . With extensive progress in generating knock-out mouse models and using new technologies to define existing mouse models, the number of mouse models available to study SLE is on the increase: a comprehensive list of 45 mouse models currently associated with the disease SLE can be obtained by a simple search of the Mouse Genome Informatics database, a database hosted by the Jackson Laboratory, USA (http://www.informatics.jax.org/) . The orthologous disease-associated genes for both mouse and human are also clearly documented and show the extent of the overlap between disease genes for the two species. The results obtained by this search are shown in Additional file 5: Table S5. Availability of information on human genetics underlying SLE has made it increasingly possible to verify that the functional pathways underlying pathogenesis in the two species are similar [79, 82]. Thus parallel research into disease genetics underlying mouse models of SLE can inform research into the human disease, and similarly progress made in understanding genetics underlying the human disease can refine mouse models further. An example of this is the use of mouse models of SLE in the investigation of microRNA expression patterns in SLE .
Research to date has identified multiple facets of SLE, including a better understanding of the cellular and environmental processes leading to the disease state as well as genetic abnormalities that are associated with the disease. There have been many advances in understanding genetic factors that are associated with the disease – in many cases through GWAS – but there is still a pressing need to interpret such factors with regard to their biological impact. The way in which fundamental immune and biological responses are perturbed by these genetic factors needs to be better understood before there can be similar advances in the diagnostic, prognostic and therapeutic management of SLE for maximum benefit to the patient.
Systemic lupus erythematosus
Pathogen-associated molecular patterns
Damage-associated molecular patterns
Genome-wide association study
Single Nucleotide Polymorphism
Copy number variation
Quantitative trait loci.
NT is funded by the Medical Research Council of South Africa. The authors declare no conflicts of interest in the publication of this review.
- Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med. 2008, 358 (9): 929-939. 10.1056/NEJMra071297.PubMedView ArticleGoogle Scholar
- Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8 (6): 492-502. 10.1038/sj.gene.6364408.PubMed CentralPubMedView ArticleGoogle Scholar
- Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003, 349 (16): 1526-1533. 10.1056/NEJMoa021933.PubMedView ArticleGoogle Scholar
- Pathak S, Mohan C: Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models. Arthritis Res Ther. 2011, 13 (5): 241-10.1186/ar3465.PubMed CentralPubMedView ArticleGoogle Scholar
- Kyttaris VC: Systemic lupus erythematosus: from genes to organ damage. Methods Mol Biol. 2010, 662: 265-283. 10.1007/978-1-60761-800-3_13.PubMed CentralPubMedView ArticleGoogle Scholar
- Fessel WJ: Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med. 1974, 134: 1027-1035. 10.1001/archinte.1974.00320240061006.PubMedView ArticleGoogle Scholar
- Danchenko N, Satia JA, Anthony MS: Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006, 15 (5): 308-318. 10.1191/0961203306lu2305xx.PubMedView ArticleGoogle Scholar
- Tikly M, Navarra SV: Lupus in the developing world–is it any different?. Best Pract Res Clin Rheumatol. 2008, 22 (4): 643-655. 10.1016/j.berh.2008.05.003.PubMedView ArticleGoogle Scholar
- Systemic lupus erythematosus - an update. Drug Ther Bull. 49 (7): 81-84.
- Nightingale AL, Farmer RD, de Vries CS: Incidence of clinically diagnosed systemic lupus erythematosus 1992–1998 using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf. 2006, 15 (9): 656-661. 10.1002/pds.1199.PubMedView ArticleGoogle Scholar
- Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ: Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum. 2007, 57 (4): 612-618. 10.1002/art.22683.PubMedView ArticleGoogle Scholar
- Adebajo AO: Low frequency of autoimmune disease in tropical Africa. Lancet. 1997, 349 (9048): 361-362.PubMedView ArticleGoogle Scholar
- Minaur N, Sawyers S, Parker J, Darmawan J: Rheumatic disease in an Australian aboriginal community in North Queensland Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004, 31 (5): 965-972.PubMedGoogle Scholar
- Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM, Ferraz MB: Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol. 2004, 31 (3): 594-597.PubMedGoogle Scholar
- Molokhia M, McKeigue PM, Cuadrado M, Hughes G: Systemic lupus erythematosus in migrants from west Africa compared with afro-caribbean people in the UK. Lancet. 2001, 357 (9266): 1414-1415. 10.1016/S0140-6736(00)04580-3.PubMedView ArticleGoogle Scholar
- Bae SC, Fraser P, Liang MH: The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis". Arthritis Rheum. 1998, 41 (12): 2091-2099. 10.1002/1529-0131(199812)41:12<2091::AID-ART2>3.0.CO;2-D.PubMedView ArticleGoogle Scholar
- Molokhia M, McKeigue P: Systemic lupus erythematosus: genes versus environment in high risk populations. Lupus. 2006, 15 (11): 827-832. 10.1177/0961203306070007.PubMedView ArticleGoogle Scholar
- Clatworthy MR, Willcocks L, Urban B, Langhorne J, Williams TN, Peshu N, Watkins NA, Floto RA, Smith KG: Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A. 2007, 104 (17): 7169-7174. 10.1073/pnas.0608889104.PubMed CentralPubMedView ArticleGoogle Scholar
- Namjou B, Kothari PH, Kelly JA, Glenn SB, Ojwang JO, Adler A, Alarcon-Riquelme ME, Gallant CJ, Boackle SA, Criswell LA, et al: Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011, 12 (4): 270-279. 10.1038/gene.2010.73.PubMed CentralPubMedView ArticleGoogle Scholar
- Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J: Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus. 2008, 17 (5): 371-375. 10.1177/0961203308089990.PubMedView ArticleGoogle Scholar
- Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH: Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun. 2004, 22 (2): 139-145. 10.1016/j.jaut.2003.11.003.PubMedView ArticleGoogle Scholar
- Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG: Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006, 65 (1): 57-63. 10.1136/ard.2005.035733.PubMed CentralPubMedView ArticleGoogle Scholar
- Savill J, Dransfield I, Gregory C, Haslett C: A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002, 2 (12): 965-975. 10.1038/nri957.PubMedView ArticleGoogle Scholar
- Matzinger P: The danger model: a renewed sense of self. Science. 2002, 296 (5566): 301-305. 10.1126/science.1071059.PubMedView ArticleGoogle Scholar
- Ardoin SP, Pisetsky DS: Developments in the scientific understanding of lupus. Arthritis Res Ther. 2008, 10 (5): 218-10.1186/ar2488.PubMed CentralPubMedView ArticleGoogle Scholar
- Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, et al: Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med. 2005, 11 (2): 138-145. 10.1038/nm1176.PubMedView ArticleGoogle Scholar
- Marshak-Rothstein A: Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006, 6 (11): 823-835. 10.1038/nri1957.PubMedView ArticleGoogle Scholar
- von Landenberg P, Bauer S: Nucleic acid recognizing Toll-like receptors and autoimmunity. Curr Opin Immunol. 2007, 19 (6): 606-610. 10.1016/j.coi.2007.10.004.PubMedView ArticleGoogle Scholar
- Roth R, Nakamura T, Mamula MJ: B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. J Immunol. 1996, 157 (7): 2924-2931.PubMedGoogle Scholar
- Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006, 4 (7): 437-447. 10.1158/1541-7786.MCR-06-0007.PubMedView ArticleGoogle Scholar
- Tveita AA, Rekvig OP, Zykova SN: Increased glomerular matrix metalloproteinase activity in murine lupus nephritis. Kidney Int. 2008, 74 (9): 1150-1158. 10.1038/ki.2008.308.PubMedView ArticleGoogle Scholar
- Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL: Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med. 1975, 59 (4): 533-552. 10.1016/0002-9343(75)90261-2.PubMedView ArticleGoogle Scholar
- Block SR: A brief history of twins. Lupus. 2006, 15 (2): 61-64. 10.1191/0961203306lu2263ed.PubMedView ArticleGoogle Scholar
- Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM: A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992, 35 (3): 311-318. 10.1002/art.1780350310.PubMedView ArticleGoogle Scholar
- Alarcon-Segovia D, Alarcon-Riquelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR, Pons-Estel BA: Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 2005, 52 (4): 1138-1147. 10.1002/art.20999.PubMedView ArticleGoogle Scholar
- Hochberg MC: The application of genetic epidemiology to systemic lupus erythematosus. J Rheumatol. 1987, 14 (5): 867-869.PubMedGoogle Scholar
- Lawrence JS, Martins CL, Drake GL: A family survey of lupus erythematosus. 1. Heritability. J Rheumatol. 1987, 14 (5): 913-921.PubMedGoogle Scholar
- Deng Y, Tsao BP: Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010, 6 (12): 683-692. 10.1038/nrrheum.2010.176.PubMed CentralPubMedView ArticleGoogle Scholar
- Risch NJ: Searching for genetic determinants in the new millennium. Nature. 2000, 405 (6788): 847-856. 10.1038/35015718.PubMedView ArticleGoogle Scholar
- Zeggini E, Ioannidis JP: Meta-analysis in genome-wide association studies. Pharmacogenomics. 2009, 10 (2): 191-201. 10.2217/146224126.96.36.199.PubMed CentralPubMedView ArticleGoogle Scholar
- Iles MM: What can genome-wide association studies tell us about the genetics of common disease?. PLoS Genet. 2008, 4 (2): e33-10.1371/journal.pgen.0040033.PubMed CentralPubMedView ArticleGoogle Scholar
- Altshuler D, Daly M: Guilt beyond a reasonable doubt. Nat Genet. 2007, 39 (7): 813-815. 10.1038/ng0707-813.PubMedView ArticleGoogle Scholar
- Kingsley CB: Identification of causal sequence variants of disease in the next generation sequencing era. Methods Mol Biol. 2011, 700: 37-46. 10.1007/978-1-61737-954-3_3.PubMedView ArticleGoogle Scholar
- Ramos PS, Williams AH, Ziegler JT, Comeau ME, Guy RT, Lessard CJ, Edberg JC, Zidovetzki R, Criswell LA, Gaffney PM, et al: Genetic analyses of interferon pathway-related genes reveals multiple new loci associated with systemic lupus erythematosus (SLE). Arthritis Rheum. 2011, 63 (7): 2049-2057. 10.1002/art.30356.PubMed CentralPubMedView ArticleGoogle Scholar
- Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, et al: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008, 58 (1): 15-25. 10.1002/art.23177.PubMedView ArticleGoogle Scholar
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000, 25 (1): 25-29. 10.1038/75556.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhou J, Wu R, High AA, Slaughter CA, Finkelstein D, Rehg JE, Redecke V, Hacker H: A20-binding inhibitor of NF-kappaB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein beta activation and protects from inflammatory disease. Proc Natl Acad Sci U S A. 2011, 108 (44): E998-E1006. 10.1073/pnas.1106232108.PubMed CentralPubMedView ArticleGoogle Scholar
- Yan K, Cao Q, Reilly CM, Young NL, Garcia BA, Mishra N: Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. J Biol Chem. 2011, 286 (33): 28833-28843. 10.1074/jbc.M111.233932.PubMed CentralPubMedView ArticleGoogle Scholar
- Reilly CM, Regna N, Mishra N: HDAC inhibition in lupus models. Mol Med. 2011, 17 (5–6): 417-425.PubMed CentralPubMedGoogle Scholar
- Yu HH, Liu PH, Lin YC, Chen WJ, Lee JH, Wang LC, Yang YH, Chiang BL: Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus. 2010, 19 (10): 1219-1228. 10.1177/0961203310371152.PubMedView ArticleGoogle Scholar
- Glazier AM, Nadeau JH, Aitman TJ: Finding genes that underlie complex traits. Science. 2002, 298 (5602): 2345-2349. 10.1126/science.1076641.PubMedView ArticleGoogle Scholar
- Barnes MR: Navigating the HapMap. Brief Bioinform. 2006, 7 (3): 211-224. 10.1093/bib/bbl021.PubMedView ArticleGoogle Scholar
- Luo X, Yang W, Ye DQ, Cui H, Zhang Y, Hirankarn N, Qian XX, Tang Y, Lau YL, De Vries N, et al: A functional variant in microrna-146a promoter modulates its expression and confers disease risk for Systemic Lupus Erythematosus. PLoS Genet. 2011, 7 (6): e1002128-10.1371/journal.pgen.1002128.PubMed CentralPubMedView ArticleGoogle Scholar
- Wong KK, de Leeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, MacAulay C, Ng RT, Brown CJ, Eichler EE, et al: A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet. 2007, 80 (1): 91-104. 10.1086/510560.PubMed CentralPubMedView ArticleGoogle Scholar
- Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, Hebert M, Jones KN, Shu Y, Kitzmiller K, et al: Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet. 2007, 80 (6): 1037-1054. 10.1086/518257.PubMed CentralPubMedView ArticleGoogle Scholar
- Walport MJ: Complement. First of two parts. N Engl J Med. 2001, 344 (14): 1058-1066. 10.1056/NEJM200104053441406.PubMedView ArticleGoogle Scholar
- Ptacek T, Li X, Kelley JM, Edberg JC: Copy number variants in genetic susceptibility and severity of systemic lupus erythematosus. Cytogenet Genome Res. 2008, 123 (1–4): 142-147.PubMedView ArticleGoogle Scholar
- Thai TH, Christiansen PA, Tsokos GC: Is there a link between dysregulated miRNA expression and disease?. Discov Med. 2010, 10 (52): 184-194.PubMedGoogle Scholar
- Dai R, Ahmed SA: MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011, 157 (4): 163-179. 10.1016/j.trsl.2011.01.007.PubMed CentralPubMedView ArticleGoogle Scholar
- Nelson P, Kiriakidou M, Sharma A, Maniataki E, Mourelatos Z: The microRNA world: small is mighty. Trends Biochem Sci. 2003, 28 (10): 534-540. 10.1016/j.tibs.2003.08.005.PubMedView ArticleGoogle Scholar
- Davidson-Moncada J, Papavasiliou FN, Tam W: MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci. 2010, 1183: 183-194. 10.1111/j.1749-6632.2009.05121.x.PubMed CentralPubMedView ArticleGoogle Scholar
- Wahid F, Shehzad A, Khan T, Kim YY: MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010, 1803 (11): 1231-1243. 10.1016/j.bbamcr.2010.06.013.PubMedView ArticleGoogle Scholar
- Tsitsiou E, Lindsay MA: microRNAs and the immune response. Curr Opin Pharmacol. 2009, 9 (4): 514-520. 10.1016/j.coph.2009.05.003.PubMed CentralPubMedView ArticleGoogle Scholar
- Pauley KM, Cha S, Chan EK: MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009, 32 (3–4): 189-194.PubMed CentralPubMedView ArticleGoogle Scholar
- Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, Xu ZM, Yin YB: Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 2007, 16 (12): 939-946. 10.1177/0961203307084158.PubMedView ArticleGoogle Scholar
- Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y: Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 2009, 29 (7): 749-754. 10.1007/s00296-008-0758-6.PubMedView ArticleGoogle Scholar
- Te JL, Dozmorov IM, Guthridge JM, Nguyen KL, Cavett JW, Kelly JA, Bruner GR, Harley JB, Ojwang JO: Identification of unique microRNA signature associated with lupus nephritis. PLoS One. 2010, 5 (5): e10344-10.1371/journal.pone.0010344.PubMed CentralPubMedView ArticleGoogle Scholar
- Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X, Li J, Zhou H, Tang Y, Shen N: MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol. 2010, 184 (12): 6773-6781. 10.4049/jimmunol.0904060.PubMedView ArticleGoogle Scholar
- Stagakis E, Bertsias G, Verginis P, Nakou M, Hatziapostolou M, Kritikos H, Iliopoulos D, Boumpas DT: Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis. 2011, 70 (8): 1493-1506.View ArticleGoogle Scholar
- Zhao S, Wang Y, Liang Y, Zhao M, Long H, Ding S, Yin H, Lu Q: MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 2011, 63 (5): 1376-1386. 10.1002/art.30196.PubMedView ArticleGoogle Scholar
- Lashine YA, Seoudi AM, Salah S, Abdelaziz AI: Expression signature of microRNA-181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. Clin Exp Rheumatol. 2011, 29 (2): 351-357.PubMedGoogle Scholar
- Hai-yan W, Yang L, Mei-hong C, Hui Z: Expression of MicroRNA-146a in peripheral blood mononuclear cells in patients with systemic lupus Erythematosus. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011, 33 (2): 185-188.PubMedGoogle Scholar
- Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, et al: MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009, 60 (4): 1065-1075. 10.1002/art.24436.PubMedView ArticleGoogle Scholar
- Wang G, Tam LS, Li EK, Kwan BC, Chow KM, Luk CC, Li PK, Szeto CC: Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol. 2010, 37 (12): 2516-2522. 10.3899/jrheum.100308.PubMedView ArticleGoogle Scholar
- Divekar AA, Dubey S, Gangalum PR, Singh RR: Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol. 2011, 186 (2): 924-930. 10.4049/jimmunol.1002218.PubMed CentralPubMedView ArticleGoogle Scholar
- Ando Y, Maida Y, Morinaga A, Burroughs AM, Kimura R, Chiba J, Suzuki H, Masutomi K, Hayashizaki Y: Two-step cleavage of hairpin RNA with 5' overhangs by human DICER. BMC Mol Biol. 2011, 12: 6-10.1186/1471-2199-12-6.PubMed CentralPubMedView ArticleGoogle Scholar
- Hikami K, Kawasaki A, Ito I, Koga M, Ito S, Hayashi T, Matsumoto I, Tsutsumi A, Kusaoi M, Takasaki Y, et al: Association of a functional polymorphism in the 3'-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum. 2011, 63 (3): 755-763. 10.1002/art.30188.PubMedView ArticleGoogle Scholar
- Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosus. Adv Immunol. 1985, 37: 269-390.PubMedView ArticleGoogle Scholar
- Morel L: Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol. 2010, 6 (6): 348-357. 10.1038/nrrheum.2010.63.PubMedView ArticleGoogle Scholar
- Wakeland EK, Liu K, Graham RR, Behrens TW: Delineating the genetic basis of systemic lupus erythematosus. Immunity. 2001, 15 (3): 397-408. 10.1016/S1074-7613(01)00201-1.PubMedView ArticleGoogle Scholar
- Blake JA, Bult CJ, Kadin JA, Richardson JE, Eppig JT: The Mouse Genome Database (MGD): premier model organism resource for mammalian genomics and genetics. Nucleic Acids Res. 2011, 39 (Database issue): D842-D848.PubMed CentralPubMedView ArticleGoogle Scholar
- Xu Z, Morel L: Genetics of systemic lupus erythematosus: contributions of mouse models in the era of human genome-wide association studies. Discov Med. 2010, 10 (50): 71-78.PubMedGoogle Scholar
- Dai R, Zhang Y, Khan D, Heid B, Caudell D, Crasta O, Ahmed SA: Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS One. 2010, 5 (12): e14302-10.1371/journal.pone.0014302.PubMed CentralPubMedView ArticleGoogle Scholar
- Camon E, Magrane M, Barrell D, et al: The Gene Ontology Annotation (GOA) Database: sharing knowledge in Uniprot with Gene Ontology. Nucleic Acids Res. 2004, 32 (Database issue): D262-6.PubMed CentralPubMedView ArticleGoogle Scholar
- Beissbarth T, Speed TP: GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004, 20 (9): 1464-5. 10.1093/bioinformatics/bth088.PubMedView ArticleGoogle Scholar
- Zhao X, Tang Y, Qu B, et al: MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum. 2010, 62 (11): 3425-35. 10.1002/art.27632.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.